Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2011-08-30 Regulatory Filings
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings
2011-08-30 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC from the company's counsel regarding comments on Amendment No. 1 to the Registration Statement on Form S-1 filed by the company. It discusses responses to SEC comments on financial statement disclosures, accounting policies, and valuation issues related to the registration statement. The document does not contain actual financial statements or substantive financial data but is a regulatory correspondence clarifying and responding to SEC review comments. It is not the registration statement itself, nor an audit report or financial report. Given the nature of the document as a regulatory correspondence related to a filing, it fits best under Regulatory Filings (RNS).
2011-08-23 English
Regulatory Filings 2011
Regulatory Filings
2011-08-19 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from legal counsel to the SEC regarding comments on a Registration Statement on Form S-1. It discusses amendments, comments on the prospectus, risk factors, use of proceeds, and other regulatory compliance matters related to a securities offering. The document references the Form S-1 registration statement and amendments, which are filings related to securities offerings and capital raising. This is not a financial report, earnings release, or management discussion, but rather a regulatory filing responding to SEC comments on a registration statement for an offering. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2011-08-18 English
AMENDMENT NO. 1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is used for registering securities for public offering, including details about the offering, prospectus, and related disclosures. The text includes detailed information about the offering, use of proceeds, risk factors, management discussion, and other disclosures typical of a registration statement. This is not an annual report, earnings release, or any other financial report type. It is a capital raising filing related to securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2011-08-18 English
Regulatory Filings 2011
Regulatory Filings
2011-07-19 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.